Fintel reports that on March 31, 2025, RBC Capital downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.

Maroteaux-Lamy syndrome is a rare childhood disease also known as mucopolysaccharidosis type VI, MPS VI, and polydystrophic dwarfism. It’s inherited, which means it’s passed down in families.

The Department for Work and Pensions (DWP) is planning cuts to Personal Independence Payments (PIP) worth £5bn, according to ...

Liz Kendall, the work and pensions secretary, laid out plans for £5bn savings but faces rebellion from some Labour MPs.

Analysts have recently evaluated Ultragenyx Pharmaceutical and provided 12-month price targets. The average target is $104.8, accompanied by a high estimate of $140.00 and a low estimate of $48.00.

Regenxbio (RGNX) announced the closing of its previously announced strategic partnership with Nippon Shinyaku. Under the terms of the agreement, Regenxbio and Nippon Shinyaku will develop and ...

Teacher Retirement System of Texas lifted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report ...

All the health conditions that mean you qualify for Personal Independence Payments worth up to £9,584 a year have been revealed - amid sweeping Department for Work and Pensions ( DWP) cuts.

We recently published a list of Paul Singer’s Latest Portfolio: Top 10 Stock Picks. In this article, we are going to take a ...

Korea Investment CORP grew its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 362.5% ...

5 analysts have shared their evaluations of Regenxbio RGNX during the recent three months, expressing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings ...